Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BioVeda China Fund

Investor type Private Equity Firm
Founders Zhi Yang

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 16
Average round size
info
The average size of a deal this fund participated in
$43M
Portfolio companies 14
Rounds per year 0.94
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 3
Key employees 5
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Health Diagnostics
Summary

BioVeda China Fund appeared to be the VC, which was created in 2005. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.

The fund has no exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ASLAN Pharmaceuticals, DiaCarta, CARsgen Therapeutics. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.

This organization was formed by ZHI YANG. Besides them, we counted 5 critical employees of this fund in our database.

The top activity for fund was in 2014. This BioVeda China Fund works on 1 percentage points more the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 50 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 50 - 100 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the BioVeda China Fund, startups are often financed by Morningside Group, BioVeda Capital, Sanofi. The meaningful sponsors for the fund in investment in the same round are SDIC Venture Capital, New Horizon Capital, Morningside Group. In the next rounds fund is usually obtained by KTB Ventures, Jolly Innovation Ventures, 3E Bioventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BioVeda China Fund:
Typical Co-investors
BioVeda China Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BioVeda China Fund:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
6Rooms China, Shanghai
Accenture County Dublin, Dublin, Ireland
another.vc Berlin, Berlin, Germany
Cognitive Investment Seoul, Seoul-t'ukpyolsi, South Korea
Emerge Ventures, Singapore Central, Central Region, Singapore
Global Investment Technologies New York, New York, United States
Green Dot California, Pasadena, United States
Growth Source Financial Technologies India, Maharashtra, Mumbai
Huis Ten Bosch Chiba Prefecture, Futtsu, Japan
Klinkert Investment Trust -
London School of Economics and Political Science (LSE) England, London, United Kingdom
Matrix Herzliya, Israel, Tel Aviv
Ogaki Kyoritsu Bank Gifu Prefecture, Japan, Ogaki
Scopelec France, Revel, Rhone-Alpes
Sesame Street Alabama, America, United States
Standard Industries New York, New York, United States
startGBC Canada, Ontario, Toronto
TripleTree Minneapolis, Minnesota, United States
Valor Ena, Gifu Prefecture, Japan
Yaba Ziguan China, Qingpu, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Cellenkos

Biotechnology
$15M04 Nov 2021 Houston, Texas, United States

Oculis

Biotechnology
Health Care
Pharmaceutical
$57M04 May 2021 Iceland, Iceland

Biotechnology
$56M09 Feb 2021 Shanghai, China

Seinda

Health Care
Health Diagnostics
Medical Device
Product Research
23 Sep 2020 Guangzhou, Guangdong, China

BioNTech

$325M09 Jul 2019 -

Stealth BioTherapeutics

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$100M18 Jun 2018 Newton, Massachusetts, United States

MicuRx Pharmaceuticals

Biotechnology
Health Care
Medical
$15M07 Dec 2017 Hayward, California, United States

Eucure Biopharma

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
$10M01 Jul 2017 Beijing

Eucure Biopharma

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
$9M31 Dec 2016 Beijing

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BioVeda China Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: